Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.67 |
| ▸ | MYC | P01106 | 1/20 | 0.67 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.67 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471770 | 0.99 | SOAT2 (0.65) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL9081158 | 0.88 | SOAT2 (0.55) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL8704741 | 0.86 | SOAT2 (0.54) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL7109175 | 0.81 | SOAT2 (0.59) | SOAT2MYCSOAT1MAP2K3 | |
| Avasimibe SCHEMBL15876 | 0.80 | SOAT2 (1.00) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL2779847 | 0.79 | SOAT2 (0.62) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL22899813 | 0.76 | SOAT2 (0.55) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL7573425 | 0.75 | SOAT2 (0.81) | SOAT2MYCSOAT1MAP2K3LPAR1 | |
| SCHEMBL24233324 | 0.74 | SOAT2 (0.87) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7567657 | 0.74 | SOAT2 (0.79) | SOAT2MYCSOAT1MAP2K3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | ASTRAZENECA AB (SE) | 2007-07-05 | — | — | US | claimed |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | claimed |
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | claimed |
| EP-1281399-A2 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | WARNER-LAMBERT COMPANY (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0841913-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005868-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | claimed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | claimed |
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | ASTRAZENECA AB (SE) | 2007-07-05 | — | — | US | disclosed |
| EP-1682112-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044250-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| WO-1997005868-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5491172-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | SOAT2 324/4885MYC 404/4885SOAT1 704/4885 |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | ACAT2, LCAT, SOAT1 | SOAT2 5/4885MYC 2865/4885SOAT1 3/4885 |
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | GPR119, DGAT1, DGAT2 | SOAT2 17/4885MYC 2558/4885SOAT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.